MedXCRO
↗Toledo, USA
MedXCRO is a specialized Contract Research Organization (CRO) fully dedicated to the neuroscience sector. The company serves as a global development hub for therapeutic innovators, particularly in the areas of neurovascular and peripheral products. They offer end-to-end solutions including study planning, regulatory affairs, site management, and data management.
Headquartered in Toledo, Ohio, MedXCRO is known for its rapid trial startup and enrollment capabilities. It frequently partners with leading neurointerventionalists and medical device companies to execute high-stakes clinical trials for intracranial aneurysm treatments and stroke intervention technologies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$5M
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Self-funded
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 2/3 (Device IDE)
Modalities:Medical Devices, Endovascular Implants, Neuro-interventional tools
Active Trials:5
Trial Phases:Phase 1: 1 | Phase 2: 2 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Galaxy Therapeutics (SEAL Trial), Stryker (TARGET Registry), St. Vincent Mercy Medical Center
COMPETITION
Position:Niche Player
Competitors:Medpace, IQVIA, ICON plc, Neurovascular Research Group
LEADERSHIP
Key Executives:
Osama O. Zaidat, MD - Scientific Founder / Lead Investigator
M. Kaffashi - Clinical Operations Leader
Scientific Founders:Osama O. Zaidat
LINKS
Website:medxcro.co
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of MedXCRO and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with MedXCRO. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.